PMID- 25440487 OWN - NLM STAT- MEDLINE DCOM- 20150212 LR - 20150202 IS - 1879-1883 (Electronic) IS - 0002-9610 (Linking) VI - 208 IP - 6 DP - 2014 Dec TI - Metastasectomy of neuroendocrine tumors in patients with multiple endocrine neoplasia type 1. PG - 1047-53; discussion 1052-3 LID - S0002-9610(14)00439-5 [pii] LID - 10.1016/j.amjsurg.2014.08.010 [doi] AB - BACKGROUND: Neuroendocrine (NE) tumors commonly afflict patients with multiple endocrine neoplasia type 1 (MEN1). It is thought that patients with MEN1 have improved survival compared with individuals with analogous lesions. The role of metastasectomy of NE tumors in MEN1 patients is not clearly defined. METHODS: A review of MEN1 patients undergoing surgery for NE tumors from 1994 to 2010 at a single tertiary care center was performed. Tumor function, the extent of metastasis, R0 resection, and survival were analyzed. RESULTS: We identified 30 patients who underwent resection including synchronous and metachronous metastasectomy. Synchronous metastases were identified in 19 patients (63%), whereas 11 (37%) had metachronous disease. R0 resection was achieved in 93% of patients. Estimated 10-year survival is 86.4% (95% confidence interval, 60% to 100%) with no factors predictive of overall survival. The disease-free interval at 1, 5, and 10 years was 89%, 50%, and 19%, respectively, with recurrence occurring at a median of 5.4 years (95% confidence interval, 77.7% to 100%). Synchronous metastasis (P = .0072; hazard ratio [HR], 3.4) and nonfunctioning tumors (P = .014; HR, 3.3) were more likely to recur, whereas age (P = .09; HR, 1.5), gender (P = .49; HR, 1.3), and the site of metastasis (P = .81; HR, 1.1) did not influence recurrence. DISCUSSION: Patients with MEN1 benefit from resection of metastatic NE disease. Despite a high recurrence rate, survival and disease-free interval is favorable vs patients without MEN1. CI - Copyright (c) 2014 Elsevier Inc. All rights reserved. FAU - Dy, Benzon M AU - Dy BM AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Que, Florencia G AU - Que FG AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Thompson, Geoffrey B AU - Thompson GB AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Young, William F AU - Young WF AD - Department of Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Rowse, Phillip AU - Rowse P AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Strajina, Veljko AU - Strajina V AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Richards, Melanie L AU - Richards ML AD - Department of Surgery, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. Electronic address: richards.melanie@mayo.edu. LA - eng PT - Journal Article DEP - 20140922 PL - United States TA - Am J Surg JT - American journal of surgery JID - 0370473 SB - IM MH - Adult MH - Duodenal Neoplasms/*pathology/*surgery MH - Female MH - Humans MH - Male MH - *Metastasectomy MH - Middle Aged MH - Multiple Endocrine Neoplasia Type 1/*pathology/*surgery MH - Neuroendocrine Tumors/*pathology/*surgery MH - Pancreatic Neoplasms/*pathology/*surgery MH - Survival Rate MH - Treatment Outcome OTO - NOTNLM OT - MEN 1 OT - Metastasectomy OT - Neuroendocrine tumor EDAT- 2014/12/03 06:00 MHDA- 2015/02/13 06:00 CRDT- 2014/12/03 06:00 PHST- 2014/03/19 00:00 [received] PHST- 2014/08/11 00:00 [revised] PHST- 2014/08/13 00:00 [accepted] PHST- 2014/12/03 06:00 [entrez] PHST- 2014/12/03 06:00 [pubmed] PHST- 2015/02/13 06:00 [medline] AID - S0002-9610(14)00439-5 [pii] AID - 10.1016/j.amjsurg.2014.08.010 [doi] PST - ppublish SO - Am J Surg. 2014 Dec;208(6):1047-53; discussion 1052-3. doi: 10.1016/j.amjsurg.2014.08.010. Epub 2014 Sep 22.